SEATTLE--(BUSINESS WIRE)--Kineta, Inc., a biotechnology company focused on the development of immune modulating drugs for critical diseases, today announced it has been selected for a company webcast presentation at the Biotechnology Industry Organization (BIO) Annual Meeting in Philadelphia, June 17, 3 p.m. EDT. Kineta recently released safety and disease relevant data from its proof-of-concept Phase 1B clinical trial of dalazatide in patients with active plaque psoriasis. Dalazatide (formerly ShK-186) is a potent inhibitor of the Kv1.3 potassium channel, and a first in-class drug candidate that has the potential to selectively target autoimmune disease-causing cells while leaving the patient’s protective immune response unaffected. The Kv1.3 channel has been implicated in a variety of autoimmune diseases including lupus and multiple sclerosis. Kineta CEO, Dr. Charles Magness will present the recent dalazatide clinical trial as part of his Kineta corporate presentation.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
